270 Healthcare Growth

Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.

6 partners are named across this firm’s filings, 6 of them on a fund it is deploying now.

Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.

Classified sectors of 270 Healthcare Growth’s own portfolio companies, based on 25 with a verified or cited source.

• Biotech & pharma13 · 52%
• Medical devices3 · 12%
• Developer tools & infrastructure2 · 8%
• Digital health2 · 8%
• Aerospace & defense1 · 4%
• Cybersecurity1 · 4%
• Data & analytics1 · 4%
• E-commerce & marketplaces1 · 4%
• HR & future of work1 · 4%

Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of 270 Healthcare Growth’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.

A shared board seat: a company where filings name a 270 Healthcare Growth partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.